Jimenez X - Search Results

1

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.

Lu D, Jimenez X, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. Biochem Biophys Res Commun. 2004 May 28;318(2):507-13. doi: 10.1016/j.bbrc.2004.04.060. Biochem Biophys Res Commun. 2004. PMID: 15120630

2

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L. Zhu Z, et al. Among authors: jimenez x. Cancer Lett. 1999 Mar 1;136(2):203-13. doi: 10.1016/s0304-3835(98)00324-3. Cancer Lett. 1999. PMID: 10355750

3

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. J Immunol Methods. 1999 Nov 19;230(1-2):159-71. doi: 10.1016/s0022-1759(99)00135-0. J Immunol Methods. 1999. PMID: 10594363

4

An efficient route to the production of an IgG-like bispecific antibody.

Zuo Z, Jimenez X, Witte L, Zhu Z. Zuo Z, et al. Among authors: jimenez x. Protein Eng. 2000 May;13(5):361-7. doi: 10.1093/protein/13.5.361. Protein Eng. 2000. PMID: 10835110

5

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.

Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. Cancer Res. 2001 Oct 1;61(19):7002-8. Cancer Res. 2001. PMID: 11585724

6

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.

Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. Int J Cancer. 2002 Jan 20;97(3):393-9. doi: 10.1002/ijc.1634. Int J Cancer. 2002. PMID: 11774295

7

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.

Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. J Immunol Methods. 2002 Sep 15;267(2):213-26. doi: 10.1016/s0022-1759(02)00148-5. J Immunol Methods. 2002. PMID: 12165442

8

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S. Zhu Z, et al. Among authors: jimenez x. Leukemia. 2003 Mar;17(3):604-11. doi: 10.1038/sj.leu.2402831. Leukemia. 2003. PMID: 12646950

9

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. J Biol Chem. 2003 Oct 31;278(44):43496-507. doi: 10.1074/jbc.M307742200. Epub 2003 Aug 12. J Biol Chem. 2003. PMID: 12917408 Free article.

10

Di-diabody: a novel tetravalent bispecific antibody molecule by design.

Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: jimenez x. J Immunol Methods. 2003 Aug;279(1-2):219-32. doi: 10.1016/s0022-1759(03)00251-5. J Immunol Methods. 2003. PMID: 12969563

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters